Cargando…

Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET

Purpose. To assess whether the differences in vascular-metabolic relationships between lymphoma masses and colorectal liver metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-CT) combined with fluorodeoxyglucose positron emission tom...

Descripción completa

Detalles Bibliográficos
Autores principales: Miles, K. A., Williams, R. E., Yu, D., Griffiths, M. R.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094879/
https://www.ncbi.nlm.nih.gov/pubmed/21629862
http://dx.doi.org/10.1155/2011/679473
_version_ 1782203605356380160
author Miles, K. A.
Williams, R. E.
Yu, D.
Griffiths, M. R.
author_facet Miles, K. A.
Williams, R. E.
Yu, D.
Griffiths, M. R.
author_sort Miles, K. A.
collection PubMed
description Purpose. To assess whether the differences in vascular-metabolic relationships between lymphoma masses and colorectal liver metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-CT) combined with fluorodeoxyglucose positron emission tomography (FDG-PET). Methods. DCE-CT and FDG-PET studies were drawn from an imaging archive for patients with either lymphoma masses (n = 11) or hepatic metastases from colorectal cancer (CRM: n = 12). Tumour vascularity was assessed using DCE-CT measurements of perfusion. Tumour glucose metabolism was expressed as the mean FDG Standardised Uptake Value (SUV(FDG)). The relationship between metabolism and vascularity in each group was assessed from SUV(FDG) /perfusion ratios and Pearson correlation coefficients. Results. An SUV(FDG) threshold of 3.0 was used to designate lymphoma masses as active (AL, n = 6) or inactive lymphoma (IL, n = 5). Tumour perfusion was significantly higher in AL (0.65 mL/min/mL) than CRM (0.37 mL/min/mL: P = .031) despite similar SUV(FDG) (5.05 and 5.33, resp.). AL demonstrated higher perfusion values than IL (0.24 mL/min/mL: P = .006). SUV(FDG)/perfusion was significantly higher in CRM (15.3 min) than IL (4.2 min, P < .01). There was no correlation between SUV(FDG) and perfusion for any patient group.
format Text
id pubmed-3094879
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30948792011-05-31 Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET Miles, K. A. Williams, R. E. Yu, D. Griffiths, M. R. Int J Mol Imaging Clinical Study Purpose. To assess whether the differences in vascular-metabolic relationships between lymphoma masses and colorectal liver metastases predicted from previous histopathological studies can be demonstrated by dynamic contrast-enhanced CT (DCE-CT) combined with fluorodeoxyglucose positron emission tomography (FDG-PET). Methods. DCE-CT and FDG-PET studies were drawn from an imaging archive for patients with either lymphoma masses (n = 11) or hepatic metastases from colorectal cancer (CRM: n = 12). Tumour vascularity was assessed using DCE-CT measurements of perfusion. Tumour glucose metabolism was expressed as the mean FDG Standardised Uptake Value (SUV(FDG)). The relationship between metabolism and vascularity in each group was assessed from SUV(FDG) /perfusion ratios and Pearson correlation coefficients. Results. An SUV(FDG) threshold of 3.0 was used to designate lymphoma masses as active (AL, n = 6) or inactive lymphoma (IL, n = 5). Tumour perfusion was significantly higher in AL (0.65 mL/min/mL) than CRM (0.37 mL/min/mL: P = .031) despite similar SUV(FDG) (5.05 and 5.33, resp.). AL demonstrated higher perfusion values than IL (0.24 mL/min/mL: P = .006). SUV(FDG)/perfusion was significantly higher in CRM (15.3 min) than IL (4.2 min, P < .01). There was no correlation between SUV(FDG) and perfusion for any patient group. Hindawi Publishing Corporation 2011 2011-04-26 /pmc/articles/PMC3094879/ /pubmed/21629862 http://dx.doi.org/10.1155/2011/679473 Text en Copyright © 2011 K. A. Miles et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Miles, K. A.
Williams, R. E.
Yu, D.
Griffiths, M. R.
Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
title Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
title_full Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
title_fullStr Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
title_full_unstemmed Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
title_short Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET
title_sort demonstrating intertumoural differences in vascular-metabolic phenotype with dynamic contrast-enhanced ct-pet
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094879/
https://www.ncbi.nlm.nih.gov/pubmed/21629862
http://dx.doi.org/10.1155/2011/679473
work_keys_str_mv AT mileska demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet
AT williamsre demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet
AT yud demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet
AT griffithsmr demonstratingintertumouraldifferencesinvascularmetabolicphenotypewithdynamiccontrastenhancedctpet